Taltz for interleukin Psoriasis expands Rx Area in hospitals

Taltz passed through DC including SNUH, increasing Rx competition for other interleukin drugs

The statistical significance was obtained through the direct study of Tremfya

Lilly's interleukin IL-17A antagonist, Taltz, is settling on its prescription area at general hospitals.

 

According to the related industry on the 6th, psoriasis treatment Taltz (Ixekizumab) passed the drug commitee (DC) of Seoul National Hospital recently after Asan Hospital and Severance Hospital among the Big Five.

 

In addition, prescription codes have been made into major hospitals such as Seoul National University Bundang Hospital and Pusan ​​National University Hospital.

 

Taltz, which was released in late 2018, was slower to be priscribed in general hospitals compared to Janssen's IL-23 antagonist Tremfya (Guselkumab), which had entered the same period.

 

Novartis' Cosentyx (Secukinumab) which has the same mechanism as Taltz, entered the market earlier.

 

For this reason, Taltz had difficulty, but it is gradually expanding being prescribed.

 

Accordingly, the issue is how the competition between interleukin drugs in the psoriasis treatment field will change.

 

Lilly has also published the latest IXORA-R study in patients with moderate-to-severe plaque psoriasis , which directly compares the efficacy of Tremfya and Taltz.

 

As a result, the Taltz-administered group achieved a statistically significant level of skin improvement compared to the Tremfya-treated group, which achieved 41.3% of patients with complete clean skin (PASI 100), the primary endpoint at week 12.

 

All major secondary endpoints were also met.

 

The reaction rate were higher than Tremfya at the 2nd PASI 75 ratio, the 4th and 8th PASI 90 ratio, the 4th and 8th and 24th PASI 100 ratio, the 12th week's static Physician's Global Assessment (sPGA) 0 ratio, and the 1st PASI 50 ratio.

 

Andrew Blauvelt, Ph.D., working at the University of Oregon Research Center, USA, said, “The results of IXORA-R showed that Taltz is an effective treatment that helps more patients reach complete clean skin at week 12 of treatment, as early as the first week of treatment, skin plaque lesions improved by 50%”.

 

In the IXORA-R clinical trials, the safety profiles of Taltz and Tremfya were similar to those reported previously.

 

Lilly plans to announce in 2020 the results of the 24th week PASI 100 attainment rate, one of the key secondary endpoints for the IXORA-R trial.